Tearlab Corporation (TEAR) 0.79 $TEAR TearLab

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tearlab Corporation (TEAR) 0.79 $TEAR

TearLab Corporation to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016
GlobeNewswire - Mon Aug 29, 7:30AM CDT
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) has been invited to present at the 2016 Gateway Conference being held on September 7-8, 2016 at the Four Seasons Hotel San Francisco.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

TearLab Corporation Reports Second Quarter and June Year-To-Date 2016 Financial Results
GlobeNewswire - Wed Aug 03, 3:16PM CDT
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or the "Company" today reported its consolidated financial results for the second quarter and six months ended June 30, 2016. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

Medical Instrument Aug 3 Earnings Lineup: TEAR, GI & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:46AM CDT
Here, we take a look at five Medical instrument stocks set to report their second-quarter 2016 numbers on Aug 3.
TEAR: 0.79 (unch), VCYT: 5.60 (-0.03), MASI: 59.43 (+0.29), ENTL: 18.76 (-0.13), GI: 3.89 (+0.02)

TearLab Corporation to Present at the 6th Annual LD Micro Invitational
ACCESSWIRE - Thu Jun 02, 3:15PM CDT
SAN DIEGO, CA / ACCESSWIRE / June 2, 2016 / TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or the "Company", a company that develops and markets point of care ophthalmic in-vitro diagnostics, today announced that its Chief Executive Officer, Seph Jensen, will present a Company overview and business update at the 6th Annual LD Micro Invitational on Thursday, June 9, 2016 at 11:30 am PT/2:30 pm ET. The conference will be held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

TearLab Corporation Reports Q1-16 Financial Results
GlobeNewswire - Wed May 04, 3:02PM CDT
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or the "Company" today reported its consolidated financial results for the first quarter ended March 31, 2016. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

TearLab Announces $17.3 Million Registered Public Offering
GlobeNewswire - Wed May 04, 6:00AM CDT
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or the "Company" announced today the pricing of a public offering of the Company's common stock, resulting in total gross proceeds of approximately $17.3 million. The offering is expected to close on or about May 9, 2016, subject to satisfaction of customary closing conditions.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

TearLab to Release First Quarter 2016 Financial Results on May 4, 2016 - Conference Call to Follow
GlobeNewswire - Mon Apr 25, 7:30AM CDT
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or the "Company" will announce its first quarter 2016 financial results after market close on Wednesday, May 4, 2016.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

TearLab Announces First Quarter 2016 Preliminary Financial Estimates
GlobeNewswire - Wed Apr 20, 4:20PM CDT
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or "the Company" announced today certain preliminarily unaudited financial estimates for the first quarter of 2016.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

TearLab Announces Withdrawal of Proposed Public Offering of Common Stock
GlobeNewswire - Tue Feb 09, 8:00PM CST
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or the "Company" announced today that it has withdrawn the proposed underwritten public offering of its common stock, due to market conditions.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

TearLab to launch USD15.0m common stock in underwritten public offering
M2 - Tue Feb 02, 6:09AM CST
Eye care technology company TearLab (Nasdaq CM:TEAR) disclosed on Monday that it proposes to issue USD15.0m shares of its common stock in an underwritten public offering.
TEAR: 0.79 (unch)

TearLab Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Feb 01, 6:00AM CST
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or "the Company" announced today its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company currently estimates the size of the offering at $15.0 million. In addition, TearLab intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $2.25 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The proceeds of the offering will be used for general corporate purposes, including commercializing our products, research and product development, capital expenditures, and working capital.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

TearLab Announces Fourth Quarter 2015 Preliminary Financial Estimates and Provides Corporate Update
GlobeNewswire - Mon Feb 01, 6:00AM CST
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or "the Company" announced today certain preliminarily unaudited financial estimates for the fourth quarter of 2015 and provided an update on its business.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

BUYINS.NET: XPP, SIMO, SHM, ITM, AGZ, TEAR Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 30, 6:15AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ProShares Ultra FTSE China 25 (NYSE:XPP), Silicon Motion Technology Corp (NASDAQ:SIMO), SPDR Nvn Barclys Cptl Shrt Trm Mncpl Bnd (NYSE:SHM), Intema Solutions Inc (NYSE:ITM), iShares Barclays Agency Bond Fund (NYSE:AGZ), Tearlab Corp (NASDAQ:TEAR) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
XPP: 52.40 (+0.80), TEAR: 0.79 (unch), ITM: 24.73 (-0.05), SHM: 49.04 (-0.09), AGZ: 115.51 (-0.16), SIMO: 51.49 (+1.01)

TearLab to Participate in November Investor Conferences
GlobeNewswire - Wed Nov 04, 8:00AM CST
TearLab Corporation (NASDAQ:TEAR); (TSX:TLB) ("TearLab" or the "Company" announced today that it will participate in two investor conferences in November.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

TearLab Corporation to Release Q3 2015 Financial Results on November 5, 2015
GlobeNewswire - Mon Oct 19, 3:53PM CDT
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or the "Company" expects to announce its Q3 2015 financial results after market close on Thursday, November 5, 2015. TearLab is pleased to invite all willing participants in a conference call during which time financial results will be discussed. This call will be held at 4:30pm Eastern at 877-303-1593.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

Medical Necessity of Tear Osmolarity Testing in the Diagnosis and Management of Dry Eye Disease Confirmed in Recently Published Medicare Local Coverage Determination
GlobeNewswire - Fri Oct 09, 6:00AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company" announced today that First Coast Service Options, Inc. (the Medicare Area Contractor for Florida, Puerto Rico and the US Virgin Islands) has published a Local Coverage Determination (LCD) that confirms the role of tear osmolarity testing in the diagnosis and management of moderate to severe dry eye patients.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

TearLab to Participate in Craig-Hallum's 6th Annual Alpha Select Conference
GlobeNewswire - Thu Sep 10, 7:00AM CDT
TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or the "Company" announced today that its Chief Executive Officer, Elias Vamvakas, will present an update on the Company's business at the 6th Annual Craig-Hallum Alpha Select Conference on Thursday, September 17, 2015 at 1:30 p.m. Eastern Time at the Convene Conference Center in New York City.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

TearLab Corporation to Release Q2 2015 Financial Results on August 6, 2015
GlobeNewswire - Mon Jul 20, 8:30AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company" expects to announce its Q2 2015 financial results after market closes on Thursday, August 6, 2015. TearLab is pleased to invite all willing participants in a conference call during which time financial results will be discussed. This call will be held at 4:30pm Eastern at 877-303-1593.
TEAR: 0.79 (unch), TLB.TO: 1.05 (+0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 454

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 66

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 77

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Ventas to Showcase Investment Strategy at Real Estate Conference

Updated Category News Views 44

Ventas Engages Investors at Upcoming Conference Ventas, Inc. (NYSE: VTR) is gearing up to take part in significant investor meetings at the BofA Securities 2024 Global Real Estate Conference. This event presents a valuable chance for the company to connect with investors and share insights about its strategic direction and business model. Event Details and Participation...

Continue Reading
BioLineRx Explores Synergy in Ovarian Cancer Treatment

Updated Category News Views 151

New Hope on the Ovarian Cancer Front Every so often, something comes along and makes you stop and think—could this be the game-changer in the making? Well, what BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS just dropped at the ESMO 2026 feels a bit like that silver lining for folks fighting the uphill battle against homologous recombination (HR)-proficient ovarian...

Continue Reading
Analyst Ratings Show Confidence in Datadog and Others

Updated Category News Views 80

Recent Upgrades by Top Analysts Leading financial analysts from Wall Street have adjusted their outlooks on several prominent companies, reflecting a more optimistic market sentiment. Upgrades often signify increased confidence in a company's performance and present potential investment opportunities for savvy investors. Here, we delve into some of the standout upgrades...

Continue Reading
Unpacking the Increased Short Interest in Ventas (NYSE: VTR)

Updated Category News Views 77

Understanding Ventas's Short Interest Surge Ventas recently recorded an uptick in its short percent of float, which now stands at 25.59% since the last report. This notable development means that 9.80 million shares are currently sold short, translating to 3.19% of all regular shares available for trading. Given the trading volume, it would take traders approximately 3.33...

Continue Reading
Precigen's PAPZIMEOS: 7-Year Exclusivity & Long-Term Success

Updated Category News Views 54

Precigen's Game-Changer: PAPZIMEOS Secures Seven-Year Exclusivity Here's how you carve out a solid niche in the biotech world: deliver some killer results and snag yourself seven years in the driver’s seat. That's exactly what Precigen (NASDAQ: PGEN) has done with their PAPZIMEOS therapy, which got the stamp of approval from the FDA as the first exclusive treatment for...

Continue Reading